Smoking and Parkinson's disease: Does nicotine affect α-synuclein fibrillation?

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1794, Issue 2, 2009, Pages 282-290

  Hong, Dong Pyo ^a   Fink, Anthony L ^a   Uversky, Vladimir N ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

synuclein; Fibrillation; Hydroquinone; Intrinsically disordered protein; Misfolding; Nicotine; Parkinson's disease; Smoking

Indexed keywords

ALPHA SYNUCLEIN; ANABASINE; COTININE; HYDROQUINONE; NICOTINE; NORNICOTINE; THIOFLAVINE;

AMINO ACID SEQUENCE; ARTICLE; ATOMIC FORCE MICROSCOPY; CIGARETTE SMOKING; DISEASE ASSOCIATION; DRUG INHIBITION; DRUG STRUCTURE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NEUROPROTECTION; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN STABILITY;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; ANABASINE; CHROMATOGRAPHY, GEL; COTININE; HUMANS; HYDROQUINONES; MICROSCOPY, ATOMIC FORCE; MOLECULAR SEQUENCE DATA; MUTATION; NICOTINE; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SMOKING; THIAZOLES;

EID: 58149199681     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2008.09.026     Document Type: Article

References (46)

1. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22 (1999) 123-144
2. Lewy F.H. In: Lewandowski M. (Ed). Handbuch der Neurologie (1912), Springer, Berlin 920-933
3. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996) 259-272
4. Trojanowski J.Q., Goedert M., Iwatsubo T., and Lee V.M. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5 (1998) 832-837
5. Trojanowski J.Q., and Lee V.M. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann. N. Y. Acad. Sci. 991 (2003) 107-110
6. Uversky V.N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21 (2003) 211-234
7. Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 103 (2007) 17-37
8. Dev K.K., Hofele K., Barbieri S., Buchman V.L., and van der Putten H. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45 (2003) 14-44
9. Fink A.L. The aggregation and fibrillation of alpha-synuclein. Acc. Chem. Res. 39 (2006) 628-634
10. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
11. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., and Lansbury Jr. P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996) 13709-13715
12. Uversky V.N., Li J., and Fink A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276 (2001) 10737-10744
13. Maroteaux L., Campanelli J.T., and Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8 (1988) 2804-2815
14. Uversky V.N., and Fink A.L. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett. 522 (2002) 9-13
15. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
16. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
17. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., and de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004) 164-173
18. Li J., Uversky V.N., and Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40 (2001) 11604-11613
19. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Harper J.D., Williamson R.E., and Lansbury Jr. P.T. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann. N. Y. Acad. Sci. 920 (2000) 42-45
20. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury Jr. P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 571-576
21. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002) 600-606
22. Fratiglioni L., and Wang H.X. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav. Brain Res. 113 (2000) 117-120
23. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 27 (2004) 561-568
24. Newhouse P.A., Potter A., and Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 11 (1997) 206-228
25. Fagerstrom K.O., Pomerleau O., Giordani B., and Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl) 116 (1994) 117-119
26. Kelton M.C., Kahn H.J., Conrath C.L., and Newhouse P.A. The effects of nicotine on Parkinson's disease. Brain Cogn. 43 (2000) 274-282
27. Newman M.B., Arendash G.W., Shytle R.D., Bickford P.C., Tighe T., and Sanberg P.R. Nicotine's oxidative and antioxidant properties in CNS. Life Sci. 71 (2002) 2807-2820
28. Uversky V.N., Yamin G., Souillac P.O., Goers J., Glaser C.B., and Fink A.L. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 517 (2002) 239-244
29. Nielsen L., Khurana R., Coats A., Frokjaer S., Brange J., Vyas S., Uversky V.N., and Fink A.L. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 40 (2001) 6036-6046
30. Groenning M., Olsen L., van de Weert M., Flink J.M., Frokjaer S., and Jorgensen F.S. Study on the binding of Thioflavin T to beta-sheet-rich and non-beta-sheet cavities. J. Struct. Biol. 158 (2007) 358-369
31. Boraud T., Bezard E., Bioulac B., and Gross C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124 (2001) 546-557
32. Singh N., Pillay V., and Choonara Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81 (2007) 29-44
33. Ono K., Hirohata M., and Yamada M. Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases. Exp. Neurol. 205 (2007) 414-424
34. Urbanc B., Cruz L., Le R., Sanders J., Ashe K.H., Duff K., Stanley H.E., Irizarry M.C., and Hyman B.T. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13990-13995
35. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
36. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., and Lansbury Jr. P.T. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322 (2002) 1089-1102
37. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury Jr. P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418 (2002) 291
38. Lansbury Jr. P.T. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3342-3344
39. Goldberg M.S., and Lansbury Jr. P.T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?. Nat. Cell Biol. 2 (2000) E115-E119
40. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 (1999) 8876-8884
41. Janson J., Ashley R.H., Harrison D., McIntyre S., and Butler P.C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48 (1999) 491-498
42. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., and Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002) 507-511
43. Rochet J.C., Outeiro T.F., Conway K.A., Ding T.T., Volles M.J., Lashuel H.A., Bieganski R.M., Lindquist S.L., and Lansbury P.T. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23 (2004) 23-34
44. Lansbury P.T., and Lashuel H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443 (2006) 774-779
45. Lashuel H.A., and Lansbury Jr. P.T. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?. Q. Rev. Biophys. 39 (2006) 167-201
46. Hong D.-P., Fink Jr. A.L., and Uversky V.N. Structural characteristics of the alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 383 (2008) 214-223